The irritable bowel syndrome during pregnancy

Gastroenterology Clinics of North America

Volumn 32, Issue 1, 2003, Pages 385-406

  Hasler, William L ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b Box 0362 ^*  (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRAQUINONE; ANTIDIARRHEAL AGENT; ATROPINE PLUS DIPHENOXYLATE; CALCIUM CHANNEL BLOCKING AGENT; CASCARA; CASTOR OIL; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIMETROPIUM; COLESTYRAMINE; DANTRON; DOCUSATE SODIUM; FENTANYL; KAOLIN; LACTULOSE; LAXATIVE; LOPERAMIDE; MACROGOL; MAGNESIUM HYDROXIDE; MEBEVERINE; METHACHOLINE; MINERAL OIL; OPIATE; OTILONIUM BROMIDE; PECTIN; PHENOLPHTHALEIN; PINAVERIUM; SORBITOL; SPASMOLYTIC AGENT; TRIMEBUTINE; UNINDEXED DRUG;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ALTERNATIVE MEDICINE; AUTONOMIC DYSFUNCTION; BRAIN HEMORRHAGE; CENTRAL NERVOUS SYSTEM DISEASE; CHOLESTASIS; CLINICAL FEATURE; CLINICAL TRIAL; CONGENITAL HEART DISEASE; CONGENITAL MALFORMATION; CONSTIPATION; CYANOSIS; DEFECATION; DIARRHEA; DIET SUPPLEMENTATION; DIET THERAPY; DIETARY FIBER; DRUG SAFETY; DYSPHAGIA; FETOTOXICITY; FETUS MALFORMATION; GASTROINTESTINAL TRACT FUNCTION; GENDER; GENITAL MALFORMATION; HUMAN; HYPOTENSION; INSOMNIA; IRRITABILITY; IRRITABLE COLON; LIMB MALFORMATION; MALABSORPTION; META ANALYSIS; MUSCLE HYPERTONIA; NEONATAL HEMORRHAGE; NEONATAL RESPIRATORY DISTRESS SYNDROME; NONHUMAN; PATHOGENESIS; PATHOPHYSIOLOGY; PHYSICAL EXAMINATION; PREGNANCY; PREMATURITY; PSYCHOPHARMACOTHERAPY; PSYCHOTHERAPY; REVIEW; SEIZURE; SIDE EFFECT; SIGMOIDOSCOPY; SPONTANEOUS ABORTION; TERATOGENICITY; TREATMENT OUTCOME; UTERUS CONTRACTION; VITAMIN DEFICIENCY; WITHDRAWAL SYNDROME;

ANTIDEPRESSIVE AGENTS; COLONIC DISEASES, FUNCTIONAL; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; PARASYMPATHOLYTICS; PREGNANCY; PREGNANCY COMPLICATIONS;

EID: 0037336925     PISSN: 08898553     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0889-8553(02)00136-X     Document Type: Review

References (111)

1. Thompson WG, Longstreth G, Drossman DA, et al. Functional bowel disorders and functional abdominal pain. In: Drossman DA, Corazziari E, Talley NJ, Thompson WG, Whitehead WE, editors. Rome II: The functional gastrointestinal disorders. 2nd edition. McLean (VA): Degnon Associates; 2000. p 351-432.
2. Jackson NA, Houghton LA, Whorwell PJ, Currer B. Does the menstrual cycle affect anorectal physiology? Dig Dis Sci 1994;39:2607-11.
3. Greenhalf JO, Leonard HS. Laxative in the treatment of constipation in pregnant and breast-feeding mother. Practitioner 1973;210:259-63.
4. Levy N, Lemberg E, Sharf M. Bowel habits in pregnancy. Digestion 1977;4:216-22.
5. Heitkemper MM, Jarrett M. Pattern of gastrointestinal and somatic symptoms across the menstrual cycle. Gastroenterology 1992;102:505-13.
6. Kane SV, Sable K, Hanauer SB. The menstrual cycle and its effect on inflammatory bowel disease and irritable bowel syndrome: a prevalence study. Am J Gastroenterol 1998;93:1867-72.
7. Lee OY, Mayer EA, Schmulson M, et al. Gender-related differences in IBS symptoms. Am J Gastroenterol 2001;96:2184-93.
8. Moore J, Barlow D, Jewell D, Kennedy S. Do gastrointestinal symptoms vary with the menstrual cycle? Br J Obstet Gynaecol 1998;105:1322-5.
9. Rogers J, Henry MM, Misiewicz JJ. Increased segmental activity and intraluminal pressures in the sigmoid colon of patients with the irritable bowel syndrome. Gut 1989;30:634-41.
10. Whitehead WE, Engel BT, Schuster MM. Irritable bowel syndrome: physiological and psychological differences between diarrhea-predominant and constipation-predominant patients. Dig Dis Sci 1980;25:404-13.
11. Lembo T, Naliboff BD, Matin K, et al. Irritable bowel syndrome patients show altered sensitivity to exogenous opioids. Pain 2000;87:137-47.
12. Chan YK, Herkes GK, Badcock C, et al. Alterations in cerebral potentials evoked by rectal distension in irritable bowel syndrome. Am J Gastroenterol 2001;96:2413-7.
13. Mertz H, Morgan V, Tanner G, et al. Regional cerebral activation in irritable bowel syndrome and control subjects with painful and nonpainful rectal distention. Gastroenterology 2000;118:842-8.
14. Creed F, Guthrie E. Psychological factors in the irritable bowel syndrome. Gut 1987;28:1307-18.
15. Drossman DA, Leserman J, Nachman G, et al. Sexual and physical abuse in women with functional or organic gastrointestinal disorders. Ann Intern Med 1990;113:828-33.
16. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000;95:3503-6.
17. Niec AM, Frankum B, Talley NJ. Are adverse food reactions linked to irritable bowel syndrome? Am J Gastroenterol 1998;93:2184-90.
18. Bearcroft CP, Perrett D, Farthing MJ. Postprandial plasma 5-hydroxytryptamine in diarrhoea predominant irritable bowel syndrome: a pilot study. Gut 1998;42:42-6.
19. Morris-Yates A, Talley NJ, Boyce PM, et al. Evidence of a genetic contribution to functional bowel disorder. Am J Gastroenterol 1998;93:1311-7.
20. Battaglia G, Morselli-Labate AM, Camarri E, et al. Otilonium bromide in irritable bowel syndrome: a double-blind, placebo-controlled, 15-week study. Aliment Pharmacol Ther 1998;12:1003-10.
21. Hertzberg T, Wahlbeck K. The impact of pregnancy and puerperium on panic disorder: a review. J Psychosom Obstet Gynecol 1999;20:59-64.
22. Campbell EA. Neurotic disturbance in pregnancy - a review. Psychiatr Dev 1988;6:311-28.
23. Hendrick V, Altshuler L, Cohen L, Stowe Z. Evaluation of mental health and depression during pregnancy: position paper. Psychopharmacol Bull 1998;34:297-9.
24. Altschuler LL, Hendrick V, Cohen LS. Course of mood and anxiety disorders during pregnancy and the postpartum period. J Clin Psychiatr 1998;59(Suppl 2):29-33.
25. Fava GA, Grandi S, Michelacci L, et al. Hypochondriacal fears and beliefs in pregnancy. Acta Psychiatr Scand 1990;82:70-2.
26. Savron G, Grandi S, Michelacci L, et al. Hypochondriacal symptoms in pregnancy. Psychother Psychosom 1989;52:106-9.
27. Lips HM. A longitudinal study of the reporting of emotional and somatic symptoms during and after pregnancy. Soc Sci Med 1985;21:631-40.
28. Hinds JP, Stomey B, Wald A. Does gender or the menstrual cycle affect colonic transit? Am J Gastroenterol 1989;84:123-6.
29. Kamm MA, Farthing MJ, Lennard-Jones JE. Bowel function and transit during the menstrual cycle. Gut 1989;30:605-8.
30. Turnbull GK, Thompson DG, Day S, et al. Relationships between symptoms, menstrual cycle and orocaecal transit in normal and constipated women. Gut 1989;30:30-4.
31. Wald A, Van Thiel DH, Hoechstetter L, et al. Gastrointestinal transit: the effect of the menstrual cycle. Gastroenterology 1981;80:1497-500.
32. Aytug N, Giral A, Imeryuz N, et al. Gender influence on jejunal migrating motor complex. Am J Physiol 2001;280:G255-63.
33. Cabellero-Plasencia AM, Valenzuela-Barranco M, Martin-Ruiz JL, et al. Are there changes in gastric emptying during the menstrual cycle? Scand J Gastroenterol 1999;34:772-6.
34. Knight LC, Parkman HP, Brown KL, et al. Delayed gastric emptying and decreased antral contractility in normal premenopausal women compared with men. Am J Gastroenterol 1997;92:968-75.
35. Parkman HP, Harris AD, Miller MA, Fisher R. Influence of age, gender, and menstrual cycle on the normal electrogastrogram. Am J Gastroenterol 1996;91:127-33.
36. Gill RC, Murphy PD, Hooper HR, et al. Effect of the menstrual cycle on gastric emptying. Digestion 1987;36:168-74.
37. Mones J, Carrio I, Calabuig R, et al. Influence of the menstrual cycle and of menopause on the gastric emptying rate of solids in female volunteers. Eur J Nuc Med 1993;20:600-2.
38. Bajaj P, Arendt-Neilsen L, Bajaj P, Madsen H. Sensory changes during the ovulatory phase of the menstrual cycle in healthy women. Eur J Pain 2001;5:135-44.
39. Mayer EA, Naliboff B, Lee O, et al. Review article: gender-related differences in functional gastrointestinal disorders. Aliment Pharmacol Ther 1999;13(Suppl 2):65-9.
40. Houghton LA, Jackson NA, Whorwell PJ, Morris J. Do male sex hormones protect from irritable bowel syndrome? Am J Gastroenterol 2000;95:2296-300.
41. Kamm MA, Farthing MJ, Lennard-Jones JE, et al. Steroid hormone abnormalities in women with severe idiopathic constipation. Gut 1991;32:80-4.
42. Chiloiro M, Darconza G, Piccioli E, et al. Gastric emptying and orocecal transit time in pregnancy. J Gastroenterol 2001;36:538-43.
43. Wald A, Van Thiel DH, Hoechstetter L, et al. Effect of pregnancy on gastrointestinal transit. Dig Dis Sci 1982;27:1015-8.
44. Ryan JP. Effect of pregnancy on intestinal transit: comparison or results using radioactive and non-radioactive test meals. Life Sci 1982;31:2635-40.
45. Scott LD, Lester R, Van Thiel DH, Wald A. Pregnancy-related changes in small intestinal myoelectric activity in the rat. Gastroenterology 1983;84:301-5.
46. Levy DM, William OA, Magides AD, Reilly CS. Gastric emptying is delayed at 8-12 weeks' gestation. Br J Anaesth 1994;73:237-8.
47. Macfie AG, Magides AD, Richmond MN, Reilly CS. Gastric emptying in pregnancy. Br J Anaesth 1991;67:54-7.
48. Whitehead EM, Smith M, Dean Y, O'Sullivan G. An evaluation of gastric emptying times in pregnancy and the puerperium. Anaesthesia 1993;48:53-7.
49. Ryan JP, Bhojwani A, Wang MB. Effect of pregnancy on gastric motility in vivo and in vitro in the guinea pig. Gastroenterology 1987;93:29-34.
50. Shah S, Hobbs A, Singh R, et al. Gastrointestinal motility during pregnancy: role of nitrergic component of NANC nerves. Am J Physiol 2000;279:R1478-85.
51. Mathias JR, Clench MH. Relationship of reproductive hormones and neuromuscular disease of the gastrointestinal tract. Dig Dis 1998;16:3-13.
52. Gill RC, Bowes KL, Kingma YJ. Effect of progesterone on canine colonic smooth muscle. Gastroenterology 1985;88:1941-7.
53. Oh ST, Yedidag E, Bielefeldt K. Differential effects of progesterone and its analogues on the contractility of the murine jejunum in vitro. J Surg Res 1998;75:1-15.
54. Chen TS, Doong ML, Chang FY, et al. Effects of sex steroid hormones on gastric emptying and gastrointestinal transit in rats. Am J Physiol 1995;268:G171-6.
55. Coskun T, Sevinc A, Tevetoglu I, et al. Delayed gastric emptying in conscious male rats following chronic estrogen and progesterone treatment. Res Exp Med 1995;195:49-54.
56. Walsh JW, Hasler WL, Nugent CE, Owyang C. Progesterone and estrogen are potential mediators of gastric slow-wave dysrhythmias in nausea of pregnancy. Am J Physiol 1996;270:G506-14.
57. Ryan JP, Bhojwani A. Colonic transit in rats: effect of ovariectomy, sex steroid hormones, and pregnancy. Am J Physiol 1986;251:G46-50.
58. Dawson-Basoa ME, Gintzler AR. Estrogen and progesterone activate spinal kappaopiate receptor analgesic mechanisms. Pain 1996;64:608-15.
59. Ducker TE, Boss JW, Altug SA, et al. Luteinizing hormone and human chorionic gonadotropin fragment the migrating motor complex in rat small intestine. Neurogastroenterol Motil 1996;8:95-100.
60. Bani D, Baccari MC, Quattrone S, et al. Relaxin depresses small bowel motility through a nitric oxide-mediated mechanism. Studies in mice. Biol Reprod 2002;66:778-84.
61. Manning AP, Thompson WG, Heaton KW, Morris AF. Towards positive diagnosis of the irritable bowel. BMJ 1978;2:653-4.
62. Kruis W, Thieme C, Weinzierl M, et al. A diagnostic score for the irritable bowel syndrome: its value in the exclusion of organic disease. Gastroenterology 1984;87:1-7.
63. Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999;94:2912-7.
64. Drossman DA, Whitehead WE, Camilleri M. American Gastroenterological Association medical position statement: irritable bowel syndrome. Gastroenterology 1997;112:2118-9.
65. Sanders DS, Carter MJ, Hurlstone DP, et al. Association of adult coeliac disease with irritable bowel syndrome: a case control study in patients fulfilling Rome II criteria referred to secondary care. Lancet 2001;358:1504-8.
66. Hamm LR, Sorrells SC, Harding JP, et al. Additional investigations fail to alter the diagnosis of irritable bowel syndrome in subjects fulfilling the Rome criteria. Am J Gastroenterol 1999;94:1279-82.
67. Cappell MS, Sidhom O, Colon V. A study at ten medical centers of the safety and efficacy of 48 flexible sigmoidoscopies and 8 colonoscopies during pregnancy with follow-up of fetal outcome and with comparison to control groups. Dig Dis Sci 1996;41:2353-60.
68. Muller-Lissner SA. Effect of wheat bran on weight of stool and gastrointestinal transit time: a meta analysis. BMJ 1988;296:615-7.
69. Hotz J, Plein K. Effectiveness of plantago seed husks in comparison with wheat bran on stool frequency and manifestations of irritable colon syndrome with constipation. Med Klin 1994;89:645-51.
70. Anderson AS. Dietary factors in the aetiology and treatment of constipation during pregnancy. Br J Obstet Gynaecol 1986;93:245-9.
71. Anderson AS, Whichelow MJ. Constipation during pregnancy: dietary fibre intake and the effect of fibre supplementation. Human Nutr Appl Nutr 1985;39:202-7.
72. Muller M, Jaquenoud E. Treatment of constipation in pregnant women. A multicenter study in a gynaecological practice. J Suisse Med 1995;125:1689-93.
73. Lewis JH, Weingold AB. The use of gastrointestinal drugs during pregnancy and lactation. Am J Gastroenterol 1985;80:912-23.
74. Nelson MM, Forfar JO. Association between drugs administered during pregnancy and congenital abnormalities of the fetus. BMJ 1971;1:523-7.
75. West L, Warren J, Cutts T. Diagnosis and management of irritable bowel syndrome, constipation, and diarrhea in pregnancy. Gastroenterol Clin North Am 1992;21:793-802.
76. Einarson A, Mastroiacovo P, Arnon J, et al. Prospective, controlled, muticentre study of loperamide in pregnancy. Can J Gastroenterol 2000;14:185-7.
77. Siebert JR, Barr M, Jackson JC, et al. Ebstein's anomaly and extracardiac defects. Am J Dis Child 1989;143:570-2.
78. Laatikainen T. Effect of cholestyramine and phenobarbital on pruritus and serum bile acid levels in cholestasis of pregnancy. Am J Obstet Gynecol 1978;132:501-6.
79. Patterson EC, Staszak DJ. Effects of geophagia (kaolin ingestion) on the maternal blood and embryonic development in the pregnant rat. J Nutr 1997;107:2020-5.
80. Poynard T, Naveau S, Mory B, Chaput JC. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 1994;8:499-510.
81. Poynard T, Regimbeau C, Benhamou Y. Meta-analysis of smooth muscle relaxants in the treatment of irritable bowel syndrome. Aliment Pharmacol Ther 2001;15:355-61.
82. Pittler MH, Ernst E. Peppermint oil for irritable bowel syndrome: a critical review and metaanalysis. Am J Gastroenterol 1998;93:1131-5.
83. Correy JF, Newman NM, Collins JA, et al. Use of prescription drugs in the first trimester and congenital malformations. Aust N Z J Obstet Gynaecol 1991;31:340-4.
84. Gibson GT, Colley DP, McMichael AJ, Hartshorne JM. Congenital anomalies in relation to the use of doxylamine/dicyclomine and other antenatal factors: an ongoing prospective study. Med J Aust 1981;1:410-4.
85. McCredie J, Kricker A, Elliott J, et al. The innocent bystander: doxylamine/dicyclomine/pyridoxine and congenital limb defects. Med J Aust 1984;140:525-7.
86. Rothman KJ, Fyler DC, Goldblatt A, et al. Exogenous hormones and other drug exposures of children with congenital heart disease. Am J Epidemiol 1979;109:433-9.
87. Shapiro S, Heinonen OP, Siskind V, et al. Antenatal exposure to doxylamine succinate and dicyclomine hydrochloride (Bendectin) in relation to congenital malformations, perinatal mortality rate, birth weight, and intelligence quotient score. Am J Obstet Gynecol 1977;128:480-5.
88. Sjoqvist F, Bergfors PG, Borga O, et al. Plasma disappearance of nortriptyline in a newborn infant following placental transfer from an intoxicated mother: evidence of drug metabolism. J Pediatr 1972;80:496.
89. Tack JF, Vos R, Broekaert D, et al. Influence of citalopram, a selective serotonin reuptake inhibitor, on colonic tone and sensitivity in man [abstract]. Gastroenterology 2000;118:998.
90. Broekaert D, Vos R, Gevers AM, et al. A double-blind randomised placebo-controlled crossover trial of citalopram, a selective 5-hydroxytryptamine reuptake inhibitor, in irritable bowel syndrome [abstract]. Gastroenterology 2001;120:3250.
91. Jackson JL, O'Malley PG, Tomkins G, et al. Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am J Med 2000;108:65-72.
92. Clouse RE, Prakash C, Anderson RJ, Lustman PJ. Antidepressants for functional gastrointestinal symptoms and syndromes: a meta-analysis [abstract]. Gastroenterology 2001;120:3252.
93. Eggermont E, Raveschot J, Deneve V, et al. The adverse influence of imipramine on the adaptation of the newborn infant to extrauterine life. Acta Paediatr Belg 1972;26:197-204.
94. Misri S, Sivertz K. Tricyclic drugs in pregnancy and lactation: a preliminary report. Int J Psychiatry Med 1991;21:157-71.
95. Addis A, Koren G. Safety of fluoxetine during the first trimester of pregnancy: a metaanalytical review of epidemiological studies. Psychol Med 2000;30:89-94.
96. Pastuszak A, Schick-Boschetto B, Zuber C, et al. Pregnancy outcome following first-trimester exposure to fluoxetine (Prozac). JAMA 1993;269:2246-8.
97. Kulin NA, Pastuszak A, Sage SR, et al. Pregnancy outcome following maternal use of the new selective serotonin reuptake inhibitors: a prospective controlled multicenter study. JAMA 1998;279:609-10.
98. Nordeng H, Lindemann R, Perminov KV, Reikvam A. Neonatal withdrawal syndrome after in utero exposure to selective serotonin reuptake inhibitors. Acta Paediatr 2001;90:288-91.
99. Nulman I, Rovet J, Stewart DE, et al. Neurodevelopment of children exposed in utero to antidepressant drugs. N Engl J Med 1997;336:258-62.
100. Hostetter A, Stowe ZN, Strader JR, et al. Dose of selective serotonin uptake inhibitors across pregnancy: clinical implications. Depress Anxiety 2000;11:51-7.
101. Wisner KL, Perel JM, Wheeler SB. Tricyclic dose requirements across pregnancy. Am J Psychiatry 1993;150:1541-2.
102. Suarez F, Levitt MD, Adshead J, Barkin JS. Pancreatic supplements reduce symptomatic response of healthy subjects to a high fat meal. Dig Dis Sci 1999;44:1317-21.
103. Wilson J. Use of sodium cromoglycate during pregnancy: results on 296 asthmatic women. Acta Therapeutica 1982;8:45-51.
104. Dolovitch LR, Addis A, Regis JM, et al. Benzodiazepine use in pregnancy and major malformations or oral cleft: meta-analysis of cohort and case-control studies. BMJ 1998;317:839-43.
105. Weber LW. Benzodiazepines in pregnancy - academical debate or teratogenic risk? Biol Res Pregnancy Perinatol 1985;6:151-67.
106. Talley NJ, Owen BK, Boyce P, Paterson K. Psychological treatments for irritable bowel syndrome: a critique of controlled treatment trials. Am J Gastroenterol 1996;91:277-83.
107. Heymann-Monnikes I, Arnold R, Florin I, et al. The combination of medical treatment plus multicomponent behavioral therapy is superior to medical treatment alone in the therapy of irritable bowel syndrome. Am J Gastroenterol 2000;95:981-94.
108. Houghton LA, Heyman DJ, Whorwell PJ. Symptomatology, quality of life and economic features of irritable bowel syndrome - the effect of hypnotherapy. Aliment Pharmacol Ther 1996;10:91-5.
109. Nobaek S, Johansson ML, Molin G, et al. Alteration of intestinal microflora is associated with reduction in abdominal bloating and pain in patients with irritable bowel syndrome. Am J Gastroenterol 2000;95:1231-8.
110. Bensoussan A, Talley NJ, Hing M, et al. Treatment of irritable bowel syndrome with Chinese herbal medicine: a randomized controlled trial. JAMA 1998;280:1585-9.
111. Hahn B, Watson M, Yan S, et al. Irritable bowel syndrome symptom patterns: frequency, duration, and severity. Dig Dis Sci 1998;43:2715-8.